Literature DB >> 19484491

Antitumorigenic effect of brain proline rich polypeptide-1 in human chondrosarcoma.

Karina Galoian1, Sean Scully, George McNamara, Patrick Flynn, Armen Galoyan.   

Abstract

Proline rich polypeptide (PRP-1) produced by neurosecretory cells of the hypothalamus is one of the fragments of neurophysin-vasopressin-associated glycoprotein. The primary structure of the neuropeptide PRP-1 isolated from neurosecretory granules of bovine neurohypophysis. We investigated PRP-1 action on chondrosarcoma, the second most common malignancy in bone, which primarily affects the cartilage cells. This deadly disease does not have any effective treatment. Earlier we demonstrated MYC oncogene inactivating effect by 1 lg/ml concentration brain PRP-1 In the present study we observed reduced viable sarcoma JJ012 cell numbers in comparison with control (89% growth inhibition) when treated with low concentrations of PRP-1 (0.5–1 lg/ml). Higher concentrations did not exhibit inhibitory effect. We assume that PRP-1 in low concentration impedes cell cycle progression. The fact that low concentrations of PRP-1 abolished Myc activity prompts to think that the antitumorigenic effect of PRP-1 in low concentrations is mediated through oncogene inactivation.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19484491     DOI: 10.1007/s11064-009-0009-6

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  19 in total

Review 1.  Tumor dormancy and MYC inactivation: pushing cancer to the brink of normalcy.

Authors:  Catherine M Shachaf; Dean W Felsher
Journal:  Cancer Res       Date:  2005-06-01       Impact factor: 12.701

2.  A new hypothalamic polypeptide is a regulator of myelopoiesis.

Authors:  Armen A Galoyan; Vardan S Aprikyan
Journal:  Neurochem Res       Date:  2002-04       Impact factor: 3.996

3.  Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia.

Authors:  B J Druker; M Talpaz; D J Resta; B Peng; E Buchdunger; J M Ford; N B Lydon; H Kantarjian; R Capdeville; S Ohno-Jones; C L Sawyers
Journal:  N Engl J Med       Date:  2001-04-05       Impact factor: 91.245

Review 4.  Pharmacological inactivation of MYC for the treatment of cancer.

Authors:  Dean W Felsher; Nicole Bradon
Journal:  Drug News Perspect       Date:  2003 Jul-Aug

Review 5.  Oncogene addiction versus oncogene amnesia: perhaps more than just a bad habit?

Authors:  Dean W Felsher
Journal:  Cancer Res       Date:  2008-05-01       Impact factor: 12.701

6.  Molecular mechanism of tenascin-C action on matrix metalloproteinase-1 invasive potential.

Authors:  Karine A Galoian; Nandor Garamszegi; Susanna P Garamszegi; Sean P Scully
Journal:  Exp Biol Med (Maywood)       Date:  2007-04

7.  Myc-oncogene inactivating effect by proline rich polypeptide (PRP-1) in chondrosarcoma JJ012 cells.

Authors:  Karina Galoian; Sean Scully; Armen Galoyan
Journal:  Neurochem Res       Date:  2008-07-09       Impact factor: 3.996

8.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation.

Authors:  Chi-Hwa Wu; Jan van Riggelen; Alper Yetil; Alice C Fan; Pavan Bachireddy; Dean W Felsher
Journal:  Proc Natl Acad Sci U S A       Date:  2007-07-30       Impact factor: 11.205

9.  Adenosine modulates cell growth in human epidermoid carcinoma (A431) cells.

Authors:  H B Tey; H E Khoo; C H Tan
Journal:  Biochem Biophys Res Commun       Date:  1992-09-30       Impact factor: 3.575

10.  Treatment and prophylaxis of anthrax by new neurosecretory cytokines.

Authors:  A A Galoyan; S L Grigoryan; K V Badalyan
Journal:  Neurochem Res       Date:  2006-06-28       Impact factor: 4.414

View more
  13 in total

1.  Cytostatic effect of novel mTOR inhibitor, PRP-1 (galarmin) in MDA 231 (ER-) breast carcinoma cell line. PRP-1 inhibits mesenchymal tumors.

Authors:  Karina A Galoian; Thomas H Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2011-04-15

2.  Regulation of onco and tumor suppressor MiRNAs by mTORC1 inhibitor PRP-1 in human chondrosarcoma.

Authors:  Karina A Galoian; Toumy Guettouche; Biju Issac; Amir Qureshi; H T Temple
Journal:  Tumour Biol       Date:  2013-11-01

3.  mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.

Authors:  Karina Galoian; H T Temple; Armen Galoyan
Journal:  Tumour Biol       Date:  2012-01-14

4.  Effect of cytostatic proline rich polypeptide-1 on tumor suppressors of inflammation pathway signaling in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Amir Qureshi; Parthik Patel; Rachel Price; Ashlyn S Morse; Gor Chailyan; Silva Abrahamyan; H T Temple
Journal:  Mol Clin Oncol       Date:  2016-09-02

5.  Proline rich polypeptide (PRP-1) increases the superoxide-producing and ferrihemoglobin reducing activities of cytochrome B(558) isoforms from human lymphosarcoma tissue cells.

Authors:  G M Simonyan; K A Galoian; R M Simonyan; M A Simonyan; A A Galoyan
Journal:  Neurochem Res       Date:  2011-01-07       Impact factor: 3.996

6.  Epigenetic control of cancer by neuropeptides.

Authors:  Karina Galoian; Parthik Patel
Journal:  Biomed Rep       Date:  2016-11-08

7.  Restoration of desmosomal junction protein expression and inhibition of H3K9-specific histone demethylase activity by cytostatic proline-rich polypeptide-1 leads to suppression of tumorigenic potential in human chondrosarcoma cells.

Authors:  Karina Galoian; Amir Qureshi; Gina Wideroff; H T Temple
Journal:  Mol Clin Oncol       Date:  2014-10-16

8.  Cytostatic effect of the hypothalamic cytokine PRP-1 is mediated by mTOR and cMyc inhibition in high grade chondrosarcoma.

Authors:  Karina Galoian; Thomas H Temple; Armen Galoyan
Journal:  Neurochem Res       Date:  2011-01-18       Impact factor: 3.996

9.  Analysis of IL6-protein complexes in chondrosarcoma.

Authors:  Karina Galoian; Shihua Luo; Parthik Patel
Journal:  Biomed Rep       Date:  2017-11-10

10.  Epigenetic regulation of embryonic stem cell marker miR302C in human chondrosarcoma as determinant of antiproliferative activity of proline-rich polypeptide 1.

Authors:  Karina Galoian; Amir Qureshi; Gianluca D'Ippolito; Paul C Schiller; Marco Molinari; Andrea L Johnstone; Shaun P Brothers; Ana C Paz; H T Temple
Journal:  Int J Oncol       Date:  2015-06-18       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.